“Our proven GPCR structure-based drug discovery platform enabled us to rapidly advance ACCG-2671 as the lead amylin receptor agonist. We are now developing a series of amylin-based drug ...

Amylin Pharmaceuticals , a San Diego-based biotechnology ... as one of the leaders in diabetes treatment. It is an injectible chemical that appears to be incredibly good at lowering levels of ...

Caption The image shows the structure of the amyloid fibrils in the wild-type amylin and also in the S20G variant. On the left of the image, fibrils from wild-type amylin are made up from layers ...

Structure Therapeutics' oral amylin agonist to enter Phase 1 by late 2025. Unlock your all-in-one trading dashboard with real-time alerts, rankings, and stock ideas—now 60% off for Memorial Day.